tetano
Editor, Senior Moderator
Am J Obstet Gynecol. 2013 Jan 17. pii: S0002-9378(13)00051-3. doi: 10.1016/j.ajog.2013.01.015. [Epub ahead of print]
Infant outcomes among pregnant women who used oseltamivir for treatment of influenza during the H1N1 epidemic.
Xie HY, Yasseen AS 3rd, Xie RH, Fell DB, Sprague AE, Liu N, Smith GN, Walker MC, Wen SW.
Source
OMNI Research Group, Department of Obstetrics & Gynecology, University of Ottawa, Ottawa, Canada; Changsha Social Work College, Hunan, P.R. China; Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, Canada.
Abstract
BACKGROUND:
This study was undertaken to examine the association between maternal oseltamivir treatment for influenza and infant outcomes during the 2009 HINI influenza pandemic.
METHODS:
This was a retrospective cohort study using a population-based maternal newborn database including women who gave birth to a singleton infant in the Canadian province of Ontario between November 2009 and April 2010. Risks of small for gestational age (SGA, 10 (th) percentile and 3 (rd) percentile), preterm birth (<37 weeks of gestation), very preterm birth (<32 weeks of gestation), and five-minute Apgar score<7 associated with maternal exposure to oseltamivir were analyzed by multivariable regression.
RESULTS:
A total of 55,355 women with a singleton birth were included in this study. Among them, 1,237(2.2%) women received oseltamivir for treatment or prevention of influenza during pregnancy. Women who took oseltamivir during pregnancy were less likely to have a SGA infant based on the 10 (th) percentile for growth (aRR 0.77; 95% confidence interval (CI) 0.60-0.98). No association between maternal use of oseltamivir with SGA on 3 (rd) percentile , preterm birth, very preterm birth and low Apgar score was observed.
CONCLUSION:
There is no evidence of an association between maternal use of oseltamivir for influenza and early birth, low Apgar at birth, and poor fetal growth.
Copyright ? 2013 Mosby, Inc. All rights reserved.
PMID:
23333544
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23333544
Infant outcomes among pregnant women who used oseltamivir for treatment of influenza during the H1N1 epidemic.
Xie HY, Yasseen AS 3rd, Xie RH, Fell DB, Sprague AE, Liu N, Smith GN, Walker MC, Wen SW.
Source
OMNI Research Group, Department of Obstetrics & Gynecology, University of Ottawa, Ottawa, Canada; Changsha Social Work College, Hunan, P.R. China; Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, Canada.
Abstract
BACKGROUND:
This study was undertaken to examine the association between maternal oseltamivir treatment for influenza and infant outcomes during the 2009 HINI influenza pandemic.
METHODS:
This was a retrospective cohort study using a population-based maternal newborn database including women who gave birth to a singleton infant in the Canadian province of Ontario between November 2009 and April 2010. Risks of small for gestational age (SGA, 10 (th) percentile and 3 (rd) percentile), preterm birth (<37 weeks of gestation), very preterm birth (<32 weeks of gestation), and five-minute Apgar score<7 associated with maternal exposure to oseltamivir were analyzed by multivariable regression.
RESULTS:
A total of 55,355 women with a singleton birth were included in this study. Among them, 1,237(2.2%) women received oseltamivir for treatment or prevention of influenza during pregnancy. Women who took oseltamivir during pregnancy were less likely to have a SGA infant based on the 10 (th) percentile for growth (aRR 0.77; 95% confidence interval (CI) 0.60-0.98). No association between maternal use of oseltamivir with SGA on 3 (rd) percentile , preterm birth, very preterm birth and low Apgar score was observed.
CONCLUSION:
There is no evidence of an association between maternal use of oseltamivir for influenza and early birth, low Apgar at birth, and poor fetal growth.
Copyright ? 2013 Mosby, Inc. All rights reserved.
PMID:
23333544
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23333544